AstraZeneca’s (AZN) Hold Rating Reaffirmed at Deutsche Bank Aktiengesellschaft

AstraZeneca (LON:AZN)‘s stock had its “hold” rating reiterated by equities researchers at Deutsche Bank Aktiengesellschaft in a research report issued on Tuesday, Digital Look reports. They currently have a £117 price objective on the biopharmaceutical company’s stock. Deutsche Bank Aktiengesellschaft’s price objective would suggest a potential downside of 6.01% from the company’s previous close.

A number of other brokerages have also recently weighed in on AZN. Citigroup increased their target price on shares of AstraZeneca from £175 to £178 and gave the stock a “buy” rating in a report on Tuesday, July 28th. Jefferies Financial Group reaffirmed a “buy” rating and set a £175 target price on shares of AstraZeneca in a research note on Wednesday, September 9th. Berenberg Bank reduced their price objective on AstraZeneca from £160 to £150 and set a “buy” rating for the company in a research report on Tuesday, September 15th. Finally, Royal Bank Of Canada reiterated an “outperform” rating and set a £145 price target on shares of AstraZeneca in a report on Tuesday, September 8th. Six investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of £150.

AstraZeneca Price Performance

Shares of AZN traded down GBX 44 during trading hours on Tuesday, reaching £124.48. The company had a trading volume of 27,813,750 shares, compared to its average volume of 30,410,363. AstraZeneca has a 12-month low of £109.22 and a 12-month high of £157.32. The company has a current ratio of 0.89, a quick ratio of 0.59 and a debt-to-equity ratio of 64.10. The firm has a 50 day simple moving average of £121.73 and a 200-day simple moving average of £133.31. The company has a market capitalization of £193.06 billion, a price-to-earnings ratio of 18.63, a PEG ratio of 0.86 and a beta of 0.20.

Insider Transactions at AstraZeneca

In other news, insider Michel Demare acquired 2,500 shares of the firm’s stock in a transaction dated Monday, September 14th. The stock was bought at an average price of £121.21 per share, with a total value of £303,025. Insiders own 0.15% of the company’s stock.

About AstraZeneca

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.
Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.